Decheng Capital LLC 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Decheng Capital LLC disclosed 14 US equity positions worth $661.3m in its Q1 2026 13F filing. The largest position was CGON at 65.2% of the reported book, followed by NUVB and UPB.
What did Decheng Capital LLC own in Q1 2026? Top 14 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | Healthcare | 65.2% | $431.2m | 6,371,669 | – | |
| 2 | NUVB Nuvation Bio Inc. | Healthcare | 16.8% | $111.3m | 25,954,439 | – | |
| 3 | UPB Upstream Bio Inc. | 3.7% | $24.5m | 2,724,868 | – | ||
| 4 | ACRS Aclaris Therapeutics, Inc. | Healthcare | 2.3% | $15.2m | 4,041,736 | – | |
| 5 | AARD AARDVARK THERAPEUTICS INC | 2.2% | $14.8m | 3,917,299 | – | ||
| 6 | LYEL Lyell Immunopharma, Inc. | 2.1% | $13.9m | 692,050 | – | ||
| 7 | NEWAMSTERDAM PHARMA CO NV | 1.6% | $10.4m | 325,057 | – | ||
| 8 | RCUS Arcus Biosciences, Inc | Healthcare | 1.6% | $10.3m | 477,819 | – | |
| 9 | RVMD REVOLUTION MEDICINES INC(NSM) | Healthcare | 1.4% | $9.1m | 93,500 | – | |
| 10 | EQ Equillium Inc. | 1.3% | $8.9m | 4,447,308 | – | ||
| 11 | BYSI BeyondSpring Inc. | 0.9% | $6.2m | 3,800,702 | – | ||
| 12 | ZNTL Zentalis Pharmaceuticals Inc. | Healthcare | 0.5% | $3.1m | 1,323,327 | – | |
| 13 | KRYS KRYSTAL BIOTECH INC | Healthcare | 0.3% | $1.9m | 7,300 | – | |
| 14 | PYXS Pyxis Oncology, Inc (formerly Apexigen) | 0.1% | $477.1k | 326,810 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.